UBS: Give WuXi Biologics (02269) a "buy" rating with a target price of HK $142

1
1
Favorite

UBS: Give WuXi Biologics (02269) a "buy" rating with a target price of HK $142

智通财经2021-08-30

Zhitong Finance APP learned that UBS issued a research report stating that it gave WuXi Biologics (02269) a "buy" rating with a target price of HK $142, and raised its 2021-23 earnings per share forecast by 26% to 38% to reflect the epidemic and CMO-related projects were stronger than expected, and the 2020-24 revenue forecast was raised by 11% to reflect the stronger-than-expected growth of new crown projects and the growth of drug production outsourcing (CMO). According to the report, according to the management, there will be at least four to five non-Novel Coronavirus-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021...

Web link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

记事本2020
·2021-08-30
666
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2163012390?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","is_english":false,"pubTime":"2021-08-30 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2163012390","market":"hk","top_or_hot":-1,"title":"UBS: Give WuXi Biologics (02269) a \"buy\" rating with a target price of HK $142","media":"智通财经","content":"<p><div>Zhitong Finance APP learned that UBS issued a research report stating that it gave WuXi Biologics (02269) a \"buy\" rating with a target price of HK $142, and raised its 2021-23 earnings per share forecast by 26% to 38% to reflect the epidemic and CMO-related projects were stronger than expected, and the 2020-24 revenue forecast was raised by 11% to reflect the stronger-than-expected growth of new crown projects and the growth of drug production outsourcing (CMO). According to the report, according to the management, there will be at least four to five non-Novel Coronavirus-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021...</p><p><a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">Web link</a></div></p>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS: Give WuXi Biologics (02269) a \"buy\" rating with a target price of HK $142</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS: Give WuXi Biologics (02269) a \"buy\" rating with a target price of HK $142\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-30 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Zhitong Finance APP learned that UBS issued a research report stating that it gave WuXi Biologics (02269) a \"buy\" rating with a target price of HK $142, and raised its 2021-23 earnings per share forecast by 26% to 38% to reflect the epidemic and CMO-related projects were stronger than expected, and the 2020-24 revenue forecast was raised by 11% to reflect the stronger-than-expected growth of new crown projects and the growth of drug production outsourcing (CMO). According to the report, according to the management, there will be at least four to five non-Novel Coronavirus-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021...</p><p><a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">Web link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/549312.html","article_id":"2163012390","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2163012390","pubTimestamp":1630308776,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，瑞银发布研究报告称，予药明生物“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02269":"药明生物"},"translate_title":"UBS Group AG: WUXI BIO (02269) \"buy\" rating target price of HK $142","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"智通财经APP获悉，瑞银发布研究报告称，予药明生物(02269)“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包(CMO)增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。该行表示，据管理层指，现时未有证据美国政府将限制美国企业使用以中国为基地的CDMO企业，同时有20%药明的客户已考虑使用公司于欧美的产能以减低风险，考虑公司CDMO服务性质，假如药物于欧美生产并运往当地，将不被视作由中国出口至美国，相信可减低药物供应不稳的风险。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":811218252,"gmtCreate":1630326149476,"gmtModify":1676530269198,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3550828792714737","authorIdStr":"3550828792714737"},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811218252","repostId":2163012390,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}